C71T
CANCELLED SECTION 71
06/02/2026
Voltar para busca
Dado oficial do USPTO
BILHI
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
BILHI
ST13
US500000079244386Classe
5, 9, 42, 44
Pedido
79244386
Registro
5809424
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
38
Atualização mais recente
03/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 42, 44
Data de depósito
23/07/2018
Data de registro
23/07/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
06/02/2026
Última transação
03/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
34
Localização do titular
FR
Examinador
MACFARLANE, JAMES W
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
G. B. (pessoa física)
Representantes
Lawrence H. Binderow BINDEROW LAW OFFICES
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
HUMAN AND VETERINARY MEDICINEDIAGNOSTIC PREPARATIONS FOR DIAGNOSING AND PREDICTING BILHARZIACANCERFIBROSISKELOID SCARCIRRHOSISDIABETESCARDIAC DISEASEFOR PREPARING SAMPLESMODIFYING AND MANIPULATING CELLS AND FOR MARKINGSEPARATINGISOLATINGREPRODUCING AND CLEANING BIOPOLYMERSNUCLEIC ACIDSPROTEINSMACROMOLECULES AND BIOLOGICALLY ACTIVE SUBSTANCES; CHEMICALBIOCHEMICAL AND BIOTECHNOLOGICAL REAGENTSSOLVENTS AND INDICATORSALL FOR MEDICAL PURPOSESFOR PREPARING SAMPLESMODIFYING AND MANIPULATING CELLSFOR MARKINGSEPARATINGISOLATINGREPRODUCING AND CLEANING BIOPOLYMERSNUCLEIC ACIDSPROTEINSMACROMOLECULES AND BIOLOGICALLY ACTIVE SUBSTANCES FOR DIAGNOSTIC USEALL FOR USE IN TREATINGDIAGNOSING AND PREDICTING BILHARZIACANCERFIBROSISKELOID SCARCIRRHOSISDIABETESCARDIAC DISEASE; KITS COMPRISING PHARMACEUTICAL PREPARATIONS FOR HUMAN OR VETERINARY MEDICAL DIAGNOSTIC USE FOR PREPARING SAMPLESMODIFYING AND MANIPULATING CELLS AND FOR MARKINGSEPARATINGISOLATINGREPRODUCING AND CLEANING BIOPOLYMERSNUCLEIC ACIDSPROTEINSMACROMOLECULES AND BIOLOGICALLY ACTIVE SUBSTANCESALL FOR USE IN TREATINGDIAGNOSING AND PREDICTING BILHARZIACANCERFIBROSISKELOID SCARCIRRHOSISDIABETESCARDIAC DISEASE; PREPARATIONS FOR DETECTING GENETIC PREDISPOSITIONS FOR MEDICAL USE
Classe 9
SOFTWARE AND COMPUTER PROGRAMS FOR MEDICAL DIAGNOSIS; APPARATUS FOR PROCESSING MEDICAL DATA FOR DIAGNOSTIC PURPOSES; PROTECTION AND SECURITY EQUIPMENT FOR ESTABLISHING MEDICAL DIAGNOSTICS AND TESTSGLOVES FOR LABORATORY PURPOSESPROTECTIVE SUITS ESPECIALLY MADE FOR USE IN LABORATORIESPROTECTIVE MASKS AND SPECTACLES
Classe 42
DEVELOPMENT OF NEW TECHNOLOGY FOR OTHERS IN THE FIELD OF GENETICS AND BIOTECHNOLOGY; DEVELOPMENT OF TOOLS IN THE FORM OF SOFTWARE FOR REGULATINGMODIFYING AND CHARACTERIZING THE STATUS OF DISEASES; SCIENTIFIC RESEARCH AND DEVELOPMENT OF BIOTECHNOLOGICAL PROCESSES FOR REGULATINGMODIFYING AND CHARACTERIZING THE STATUS OF DISEASES; RESEARCH AND DEVELOPMENT FOR OTHERS IN THE FIELD OF BIOTECHNOLOGY; CUSTOM MANUFACTURE AND SYNTHESIS OF DNABIOLOGICAL ORGANISMSCELLSVIRUSESPATHOGENS AND SPECIAL GENETICALLY MODIFIED CELLS ACCORDING TO SPECIFICATIONS PROVIDED BY OTHERS FOR THE PURPOSE OF SCIENTIFICMEDICAL AND/OR LABORATORY RESEARCH; RESEARCH AND DEVELOPMENT FOR OTHERS IN THE FIELD OF GENE THERAPYDNABIOLOGICAL ORGANISMSCELLSVIRUSESPATHOGENS AND SPECIAL GENETICALLY MODIFIED CELLS FOR SCIENTIFIC OR MEDICAL USE OR FOR RESEARCH; DEVELOPMENT AND DESIGN OF ALGORITHMSDIAGNOSTIC APPARATUSMETHODS AND COMPUTER SOFTWARE IN THE MEDICAL FIELD; SCIENTIFIC RESEARCH IN THE FIELD OF GENETICS AND GENETIC ENGINEERING; MEDICAL RESEARCH; GENETIC RESEARCH; BIOLOGICAL RESEARCH SERVICES; CONDUCTING CLINICAL TRIALS FOR OTHERS; RESEARCH AND DEVELOPMENT OF MEDICAL TREATMENTS AND MEDICINES
Classe 44
MEDICAL DIAGNOSIS SERVICES; MEDICAL TESTING FOR THE DIAGNOSIS AND TREATMENT OF PERSONS; GENETIC ANALYSIS FOR MEDICAL USE; MEDICAL SCREENING; MEDICAL ADVICE REGARDING MEDICAL MATTERS; PROVIDING ON-LINE INFORMATION RELATING TO MEDICAL DIAGNOSIS AND DETECTION OF DISEASES
Publicações
Histórico de despachos e eventos da marca no USPTO.
38 publicações encontradas
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
23/07/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
17/06/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
17/07/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/12/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
18/11/2019
FIMP
FINAL DISPOSITION PROCESSED
18/11/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
23/10/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
23/07/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/05/2019
PUBO
PUBLISHED FOR OPPOSITION
07/05/2019
GPNX
NOTIFICATION PROCESSED BY IB
03/05/2019
CRSN
CORRECTION SENT TO IB
30/04/2019
CRCR
CORRECTION CREATED FOR IB
30/04/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
17/04/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17/04/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
17/04/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
29/03/2019
RFNT
REFUSAL PROCESSED BY IB
29/03/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
27/03/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/03/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
19/03/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
18/01/2019
GNRT
NON-FINAL ACTION E-MAILED
18/01/2019
CNRT
NON-FINAL ACTION WRITTEN
18/01/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
19/12/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/12/2018
ALIE
ASSIGNED TO LIE
19/12/2018
RFNT
REFUSAL PROCESSED BY IB
15/12/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/12/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
27/11/2018
RFRR
REFUSAL PROCESSED BY MPU
27/11/2018
MAFR
APPLICATION FILING RECEIPT MAILED
13/11/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/11/2018
CNRT
NON-FINAL ACTION WRITTEN
10/11/2018
DOCK
ASSIGNED TO EXAMINER
08/11/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/11/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/11/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BILHI ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.